A new method for long-lasting delivery of punicalagin to treat osteoarthritis
A novel approach to ultralong sustained delivery of punicalagin as a potential treatment for osteoarthritis
This study is testing a new way to deliver a pomegranate compound called punicalagin directly into the joints to help people with osteoarthritis, making it easier for them to manage their condition with fewer injections.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mississippi State University NIH-funded |
| Lab location | 1 site (Mississippi State, United States) |
| Project ID | NIH-10873549 on NIH RePORTER |
What this research studies
This research focuses on developing a new delivery system for punicalagin, a compound derived from pomegranate, aimed at treating osteoarthritis (OA). The approach involves creating a microparticle system that allows for sustained release of punicalagin directly into the joints, potentially reducing the need for frequent injections. Patients may receive semiannual injections to help slow the progression of OA or prevent its onset in those at high risk. The study will assess the safety and effectiveness of this innovative treatment method.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are at high risk of developing osteoarthritis or are in the early stages of the disease.
Not a fit: Patients with advanced osteoarthritis or those who do not respond to intra-articular treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a disease-modifying treatment for osteoarthritis, potentially improving joint health and quality of life for patients.
How similar studies have performed: While the approach of using punicalagin as a disease-modifying agent is novel, similar drug delivery systems have shown promise in other treatments, indicating potential for success.
Where this research is happening
Mississippi State, United States
- Mississippi State University — Mississippi State, United States (Active)
Researchers
- Principal investigator: Elder, Steven Howard — Mississippi State University
- Study coordinator: Elder, Steven Howard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.